CoChat

The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?

Open access
Böger, Christine, Behrens, Hans-Michael, Krüger, Sandra, Röcken, Christoph · 2017 · OncoImmunology
Cited by 156

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

A combined blockade of V-domain Ig suppressor of T-cell activation (VISTA) and PD-1 is a promising new cancer treatment option, which was efficient in murine tumor models and is currently tested in first phase I studies. Here, we analyzed the VISTA expression in a large and well-characterized gastric cancer (GC) cohort on 464 therapy-naive GC samples and 14 corresponding liver metastases using immunohistochemistry. Staining results were correlated with clinico-pathological characteristics, genetic alterations and survival. VISTA expression in tumor cells was detected in 41 GCs (8.8%) and 2 corresponding liver metastases (14.3%). Moreover, VISTA expression in immune cells was observed in 388 GCs (83.6%) and 6 liver metastases (42.9%). VISTA expression was associated with the Laurén phenotype, tumor localization, Epstein–Barr virus infection, KRAS- and PIK3CA-mutational status and PD-L1 expression. There was no significant correlation with patient outcome. Moreover, a change of VISTA expression in immune cells during tumor progression was observed. The co-incidence of VISTA and PD-L1 expression indicates a dual immune evasion mechanism of GC tumor cells and makes GC an interesting target for novel combined immune checkpoint inhibitor treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2017.1293215

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 156

Metadata

Authors
Böger, C., Behrens, H.-M., Krüger, S., & Röcken, C.
Venue
OncoImmunology
Published
2017-02-21
Volume
6
Issue
4
Pages
e1293215
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2590903145
Cited by
156
References
7
FWCI
5.60
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? https://app.cochat.ai/papers/10.1080/2162402x.2017.1293215
The paper
Böger, C., Behrens, H.-M., Krüger, S., & Röcken, C. (2017). The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? OncoImmunology. https://doi.org/10.1080/2162402x.2017.1293215

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.